Welcome to our dedicated page for Altria Group SEC filings (Ticker: MO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Litigation reserves, FDA rulings, and excise-tax tables make Altria Group鈥檚 disclosures some of the most intricate in consumer staples. Finding how much Marlboro drives revenue or how IQOS licensing affects margins inside a 300-page filing is time-consuming. Our platform delivers the Altria Group annual report 10-K simplified and turns dense sections on health contingencies into clear takeaways so you can focus on what moves the dividend.
With AI-powered summaries, Stock Titan converts every Altria Group quarterly earnings report 10-Q filing into plain-English insights, flags shifts in shipment volumes, and alerts you the moment an Altria Group 8-K material events explained hits EDGAR. If you鈥檝e ever searched for 鈥�Altria Group SEC filings explained simply鈥� or wondered about 鈥�understanding Altria Group SEC documents with AI,鈥� the answer is here. Our real-time feed pairs red-lined changes, financial ratios, and narrative commentary, delivering Altria Group earnings report filing analysis before the market reacts.
Below is what professionals monitor on our page:
- Altria Group insider trading Form 4 transactions and Altria Group Form 4 insider transactions real-time
- Altria Group proxy statement executive compensation details by business segment
- Altria Group executive stock transactions Form 4 patterns ahead of dividend announcements
- Regulatory alerts with Altria Group 8-K material events explained in minutes
No more wading through PDFs鈥�understanding Altria Group SEC documents with AI is now a click away.
Altria Group (MO) Q2-25 10-Q highlights
For the six months ended 6/30/25, net revenues fell 3.6% YoY to $11.36 bn while net earnings declined 41.8% to $3.46 bn (EPS $2.04 vs $3.41). The prior-year period included a $2.7 bn gain from the sale of IQOS U.S. rights. Ex-gain, operating trends were steadier: gross profit up 2.1% to $7.10 bn; operating income down 3.6% to $5.02 bn after a $873 m non-cash goodwill impairment tied to the e-vapor unit.
Segment OCI: Smokeable products rose 2.9% to $5.40 bn; oral tobacco surged 75% to $0.93 bn, offset by a $1.12 bn loss in 鈥淎ll Other鈥� (e-vapor, Horizon, etc.).
Cash & leverage: Operating cash flow increased to $2.93 bn (vs $2.80 bn), but cash & equivalents dropped to $1.29 bn from $3.13 bn at 12/31/24 following $600 m of share buybacks and $1.61 bn debt repayment. Long-term debt stands at $23.65 bn; book equity remains negative at $(3.21) bn.
Capital returns: A new $1 bn repurchase program was authorized in Jan-25; $0.6 bn completed, $0.4 bn remains. Dividends declared YTD totaled $3.45 bn ($2.04 / share).
Key events: 鈥� ITC exclusion order removed NJOY ACE from U.S. market, triggering the goodwill write-down. 鈥� No new share restrictions on subsidiaries鈥� dividend capacity. 鈥� Contingent consideration for NJOY flavor PMT approvals increased by $25 m to $45 m.
Liquidity appears sufficient with $2.6 bn unused under an October-2028 revolving credit facility, but ongoing litigation and regulatory actions remain contingencies.
FAQ
What is the current stock price of Altria Group (MO)?
What is the market cap of Altria Group (MO)?
